Abstract: The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Abstract: An adhesive device for biomedical applications is provided comprising a support and one or more water insoluble compounds of structure 1 wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L? is a urethane or urea bond, A is a chain extender of Mw?3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-triol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4 or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C.

Abstract: A biocompatible adhesive is provided comprising one or more water insoluble compounds of structure (1) wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L? is a urethane or urea bond, A is a chain extender of Mw?3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4; or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

Abstract: A water soluble biocompatible adhesive is provided comprising one or more compounds of structure 1 wherein B is an oligomer derived from a polyether or polyalkylene glycol, with a MW<5,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L? is a urethane or urea bond, A is a chain extender of Mw?3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

Abstract: The disclosure features surface coatings formed from dimeric steroid prodrugs for the extended delivery of a drug from a surface, and for the treatment of a disease or condition. Also provided herein are drug depots formed from dimeric steroid prodrugs for the extended delivery of a drug for use in combination with implantable medical devices. Said dimeric steroid prodrugs are represented by the formula D1-L-D2, wherein D1 and D2 are independently a steroid radical and L is a linker covalently linking D1 to D2.

Abstract: The present invention is directed towards articles comprising a steroid material comprising a steroid dimer and at least one therapeutic agent distributed throughout the steroid material and the use of such articles in sustained release delivery systems. Said article may be fibers, fiber meshes, woven fabrics, non-woven fabrics, films, pellets, cylinders, microparticles, nanoparticles, shaped articles or coatings on a substrate (such as an implant). Control of the release profile of the at least one therapeutic agent can be achieved via selection of the steroids within the steroid dimer, the linker conjugating the steroids within the dimer, the linkage groups between the steroids and the linker, the surface area of the article, the location of the at least one therapeutic agent within the article and the amount of the at least one therapeutic agent within the article.

Abstract: The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents.

Abstract: The invention relates to oligofluorinated coatings and their use in drag delivery. The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue. This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.

Abstract: The invention features surfaces formed from a base polymer admixed with an additive of the invention. The surfaces can be resistant to bacterial adhesion. The surfaces of the invention can be applied to: (a) any medical device or material that is implanted in or juxtaposed to a human or animal tissue or body fluid, in vivo or ex vivo, permanently or for a short period, and (b) any useful article, material or device, medical or not, which is to maintain a human or animal health-safe unfouled state of cleanliness over a period of time. In these medical and non-medical applications it is known that undesirable fouling phenomenon can take place which might harm a patient, user or consumer of the compromised device, equipment or material processed by, transported or stored in contamination prone articles, equipment or environments. Such fouling phenomena include biofilm development and bacterial colony development.

Abstract: The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Abstract: The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Abstract: Polar hydrophobic ionic materials and, in particular, polar hydrophobic ionic polyurethanes having a minimum ratio of hydrophobic and anionic components to the remainder of the polymer components are provided that exhibit reduced IgG Fab exposure.

Abstract: The invention relates to ester-linked surface-modifying macromolecules and admixtures thereof as shown below by the representative compounds. The admixtures can be used in industrial and medical applications where enhanced surface properties are desirable (e.g., surface properties reducing or preventing biofouling, immobilization of biomolecules, or denaturation of certain biomolecules).

Abstract: The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Abstract: The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Abstract: The invention relates to carbonate-linked surface modifying macromolecules and admixtures thereof. The admixtures can be used in industrial and medical applications where enhanced surface properties are desirable (e.g., surface properties reducing or preventing biofouling, immobilization of biomolecules, or denaturation of certain biomolecules).

Abstract: A soft tissue filler comprising a biodegradable amino-acid derived polycarbonate-urethanes and methods of repairing soft tissue defects are provided. The biodegradable soft tissue filler comprises a porous scaffold that is the reaction product of: a) a divinyl oligomer component that comprises a carbonate-derived divinyl oligomer that is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and a polycarbonate and, optionally, an ether-derived divinyl oligomer, wherein the ether-derived divinyl oligomer is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and an ether; b) at least one anionic monomer; and c) at least one hydrophobic monomer. The molar ratio of (a):(b+c) is between about 1:?21 and about 1:30, the soft tissue filler has a porosity of >75%; and a compressive moduli of between about 1 kPa and about 50 kPa.

Abstract: Disclosed are vascular grafts having a surface modified to reduce the risk of thrombi formation post implantation into a subject. The vascular graft can include a tubular structure comprising a base polymer admixed with an oligofluorinated additive.

Abstract: The present disclosure discloses a bone stabilization device (also referred to as a bone tape), which includes a composite flexible construct including a rigidifiable biocompatible sheet structure having first and second opposed surfaces. A biocompatible cement is located on the first surface. In use the composite flexible construct is applied to a bone with the cement contacted directly to the bone. The cement is made of a material that, once adhered to the bone, is curable to mechanically and/or ionically bond to the sheet structure and to chemically bond to the bone to achieve a permanent bond. The bone tape allows simultaneous alignment and stabilization of multiple articulated fragments for successful 3D reconstruction of shattered bones. Initial flexibility and translucency provided by the bone tape can facilitate the temporary stabilization and alignment adjustment of multiple fragments, prior to permanent rigid bonding.

Abstract: The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.